NCT01421823

A Double Blinded Study to Examine the Effect of Alpha Agonist Ointment on Fecal Incontinence in Patients With Idiopathic Fecal Incontinence

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: RDD Pharma Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the effect and safety of alpha agonist ointment on fecal incontinence severity in patients with idiopathic fecal incontinence.

Detailed description

This is a double blinded cross over study. Approximately 40 subjects will be participating in this 4 weeks study. A screening visit will be used to determine eligibility for the study. Patients found eligible will receive alpha agonist ointment or placebo ointment for 2 weeks. This will be followed by a second 2 weeks treatment cycle in which: * patients previously treated with alpha agonist will be treated with placebo. * patients previously treated with placebo will be treated with alpha agonist.

Conditions

• Idiopathic Fecal Incontinence

Interventions

Type	Name	Description
DRUG	alpha agonist ointment	2 weeks local treatment with alpha agonist ointment
DRUG	Placebo	2 weeks local treatment with placebo ointment

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-04-01
• First posted: 2011-08-23
• Last updated: 2013-12-12

Locations

1 site across 1 country: Israel